Skip to main content

Advertisement

SpringerLink
Log in

Serum microRNA-33 levels in pre-diabetic and diabetic patients

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Diabetes mellitus (DM) is a metabolic disease characterized by hyperglycemia and abnormal insulin secretion. MicroRNAs are small, non-coding RNAs that are able to affect cell biological functions and act as biomarkers for some diseases such as DM. In current study, we measured serum miR-33 in three groups (n = 15) as follows; non-diabetic control, pre-diabetic, and DM patients. Real-time PCR method was used to quantify miR-33 expression. miR-33 expression was significantly increased in pre-diabetic subjects compared to other two groups (p < 0.001). FBS (p < 0.001), insulin (p < 0.001), HOMA-IR (p < 0.001), and TG (p = 0.026) were higher in diabetic subjects than the other two groups. In people that had high physical activity, the number of diabetic subjects were zero and most of them were in pre-diabetic group (p = 0.019). Serum miR-33 level significantly and positively correlated with pre-diabetic state (B = 2.67, p = 0.000), Sex (B = 1.03, p = 0.025), and FBS (B = 0.04, p = 0.036) and also miR-33 was significantly and negatively correlated with HOMA-IR (B = − 1.58, p = 0.04). These findings support the possible role of miR-33 to monitor pre-diabetes onset and progression. It needs to be evaluated in future studies with high number of participants to clarify its mechanism and diagnostic viability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Availability of data and materials

The data that support the findings of this study are available from the corresponding author, [YMA], upon reasonable request.

References

  1. Shantikumar S, Caporali A, Emanueli C (2012) Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 93:583–593. https://doi.org/10.1093/cvr/cvr300

    Article  CAS  PubMed  Google Scholar 

  2. Guay C, Regazzi R (2013) Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9:513–521. https://doi.org/10.1038/nrendo.2013.86

    Article  CAS  PubMed  Google Scholar 

  3. Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, Ye P (2014) Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels. Dis Mark. https://doi.org/10.1155/2014/781780

    Article  Google Scholar 

  4. Aghaei Zarch SM, Dehghan Tezerjani M, Talebi M, Vahidi Mehrjardi MY (2020) Molecular biomarkers in diabetes mellitus (DM). Med J Islam Repub Iran 34:28. https://doi.org/10.34171/mjiri.34.28

    Article  PubMed  PubMed Central  Google Scholar 

  5. Vasu S, Kumano K, Darden CM, Rahman I, Lawrence MC, Naziruddin B (2019) MicroRNA signatures as future biomarkers for diagnosis of diabetes states. Cells 8:1533. https://doi.org/10.3390/cells8121533

    Article  CAS  PubMed Central  Google Scholar 

  6. Liang YZ, Li JJH, Xiao HB, He Y, Zhang L, Yan YX (2020) Identification of stress-related microRNA biomarkers in type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes 12:633–644. https://doi.org/10.1111/1753-0407.12643

    Article  CAS  PubMed  Google Scholar 

  7. Ntoumou E, Tzetis M, Braoudaki M, Lambrou G, Poulou M, Malizos K et al (2017) Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes. Ntoumou et al. Clin Epigenet 9:127. https://doi.org/10.1186/s13148-017-0428-1

    Article  CAS  Google Scholar 

  8. Jones Buie JN, Goodwin AJ, Cook JA, Halushka PV, Fan H (2016) The role of miRNAs in cardiovascular disease risk factors. Atherosclerosis 254:285–295. https://doi.org/10.1016/j.atherosclerosis.2016.09.067

    Article  CAS  Google Scholar 

  9. Karunakaran D, Richards L, Geoffrion M, Barrette D, Gotfrit RJ, Harper ME, Rayner KJ (2015) Therapeutic inhibition of miR-33 promotes fatty acid oxidation but does not ameliorate metabolic dysfunction in diet-induced obesity. Arterioscler Thromb Vasc Biol 35(12):2536–2543. https://doi.org/10.1161/ATVBAHA.115.306404

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mohammadi S, Ebrahimi-Mameghani M, Arefhosseini SR, Fallah P, Asghari Jafarabadi M, Zununi S et al (2017) Dietary regulation of miR-33b and miR-29a in relationship to metabolic biomarkers of glucose and lipids in obese diabetic women: a randomized clinical controlled study. Iran Red Crescent Med J 19(1):e37521. https://doi.org/10.5812/ircmj.37521

    Article  Google Scholar 

  11. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328:1566–1569. https://doi.org/10.1126/science.1189123

    Article  CAS  PubMed  Google Scholar 

  12. García-Rodríguez S, Arias-Santiago S, Orgaz-Molina J, Magro-Checa C, Valenzuela I, Navarro P et al (2014) Abnormal levels of expression of plasma MicroRNA-33 in patients with psoriasis. Actas Dermosifiliogr 105(5):497–503

    Article  Google Scholar 

  13. Distel E, Barrett TJ, Chung K, Girgis NM, Parathath S, Essau CC et al (2014) mir33 inhibition overcomes deleterious effects of diabetes on atherosclerosis plaque regression in mice. Circ Res 115(9):759–769. https://doi.org/10.1161/CIRCRESAHA.115.304164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006. https://doi.org/10.1038/cr.2008.282

    Article  CAS  PubMed  Google Scholar 

  15. Karolina DS, Armugam A, Sepramaniam S, Jeyaseelan K (2012) miRNAs and diabetes mellitus. Expert Rev Endocrinol Metab 7(3):281–300. https://doi.org/10.1586/eem.12.21

    Article  CAS  PubMed  Google Scholar 

  16. Kimura Y, Tamasawa N, Matsumura K, Murakami H, Yamashita M, Matsuki K et al (2016) Clinical significance of determining plasma MicroRNA33b in type 2 diabetic patients with dyslipidemia. J Atheroscler Thromb 23:1276–1285. https://doi.org/10.5551/jat.33670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Wang C, Wan S, Yang T, Niu D, Zhang A, Yang C et al (2016) Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep 6:20032. https://doi.org/10.1038/srep20032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Najafipour H, Mirzazadeh A, Haghdoost AA, Shadkam M, Afshari M, Moazenzadeh M et al (2012) Coronary artery disease risk factors in an urban and peri-urban setting, Kerman, Southeastern Iran (KERCADR Study): methodology and preliminary report. Iran J Publ Health 41(9):86–92

    CAS  Google Scholar 

  19. Ma J, Wang J, Liu Y, Wang C, Duan D, Lu N et al (2017) Comparisons of serum miRNA expression profiles in patients with diabetic retinopathy and type 2 diabetes mellitus. Clinics 72(2):111–115. https://doi.org/10.6061/clinics/2017(02)08

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cirillo PDR, Margiotti K, Mesoraca A, Giorlandino C (2020) Quantification of circulating microRNAs by droplet digital PCR for cancer detection. BMC Res Notes 13:351. https://doi.org/10.1186/s13104-020-05190-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M et al (2016) Towards a new standardized method for circulating miRNAs profling in clinical studies: interest of the exogenous normalization to improve miRNA signature accuracy. Mol Oncol 10(7):981–992

    Article  CAS  Google Scholar 

  22. Cao M, Bai L, Wang D, Zhai Q, Li Y, Hai J, Wang W (2018) miRNA-33 expression and its mechanism in patients and model rats with type 2 diabetic nephropathy. Int J Clin Exp Med 11(3):1661–1668

    Google Scholar 

  23. Deng J, Guo F (2019) MicroRNAs and type 2 diabetes. ExRNA 1:36. https://doi.org/10.1186/s41544-019-0038-5

    Article  Google Scholar 

  24. Ono K (2016) A novel link between plasma microRNA-33b levels and lipid disorders in diabetes mellitus. J Atheroscler Thromb 23:1259–1260. https://doi.org/10.5551/jat.ED056

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y et al (2011) Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48:61–69. https://doi.org/10.1007/s00592-010-0226-0

    Article  CAS  PubMed  Google Scholar 

  26. Parrizas M, Brugnara L, Esteban Y, Gonzalez-Franquesa A, Canivell S, Murillo S et al (2015) Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metab 100(3):E407–E415. https://doi.org/10.1210/jc.2014-2574

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was financially supported by Kerman University of Medical Sciences Research Council and Physiology Research Center.

Funding

This research was financially supported by Kerman University of Medical Sciences Research Council.

Author information

Authors and Affiliations

  1. Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

    Beydolah Shahouzehi

  2. Department of Biostatistics and Epidemiology School of Public Health, Kerman University of Medical Sciences, Kerman, Iran

    Mostafa Eghbalian

  3. Department of Clinical Biochemistry, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

    Hossein Fallah

  4. Physiology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Jahad Boulevard, Ebn-e-Sina Avenue, 7619813159, Kerman, Iran

    Soheil Aminizadeh & Yaser Masoumi-Ardakani

Authors
  1. Beydolah Shahouzehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mostafa Eghbalian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Fallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soheil Aminizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yaser Masoumi-Ardakani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design, data collection and analysis. The authors declare that all data were generated in-house and that no paper mill was used. Experimental procedures were performed by BS, HF, SA and YM-A. The first draft of the manuscript was written by BS and ME and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Yaser Masoumi-Ardakani.

Ethics declarations

Conflict of interest

Authors declare that there is no conflict of interest.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Patients signed informed consent regarding publishing their data.

Ethical approval

This study was approved by the Ethics Committee of Kerman University of Medical Sciences (The Ethic approval Cod is IR.KMU.REC.1396.2537) and all procedures of the current study was in accordance with standards set by the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shahouzehi, B., Eghbalian, M., Fallah, H. et al. Serum microRNA-33 levels in pre-diabetic and diabetic patients. Mol Biol Rep 48, 4121–4128 (2021). https://doi.org/10.1007/s11033-021-06425-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06425-7

Keywords

Search

Navigation